Can alpha-synuclein be targeted in novel therapies for Parkinson's disease?
Brundin, Patrik LU and Olsson, Roger LU
(2011)
In Expert Review of Neurotherapeutics
11(7).
p.917-919
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2059149
- author
- Brundin, Patrik
LU
and Olsson, Roger
LU
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Expert Review of Neurotherapeutics
- volume
- 11
- issue
- 7
- pages
- 917 - 919
- publisher
- Future Drugs Ltd
- external identifiers
-
- wos:000293853900001
- pmid:21721907
- scopus:79959965774
- pmid:21721907
- ISSN
- 1744-8360
- DOI
- 10.1586/ern.11.73
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Neuronal Survival (013212041)
- id
- 9fb0fe2a-2bac-4284-a84e-23510f492229 (old id 2059149)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21721907?dopt=Abstract
- date added to LUP
- 2016-04-04 08:36:54
- date last changed
- 2022-01-29 03:43:00
@article{9fb0fe2a-2bac-4284-a84e-23510f492229,
author = {{Brundin, Patrik and Olsson, Roger}},
issn = {{1744-8360}},
language = {{eng}},
number = {{7}},
pages = {{917--919}},
publisher = {{Future Drugs Ltd}},
series = {{Expert Review of Neurotherapeutics}},
title = {{Can alpha-synuclein be targeted in novel therapies for Parkinson's disease?}},
url = {{http://dx.doi.org/10.1586/ern.11.73}},
doi = {{10.1586/ern.11.73}},
volume = {{11}},
year = {{2011}},
}